NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis $2.57 -0.08 (-3.02%) Closing price 04:00 PM EasternExtended Trading$2.54 -0.02 (-0.97%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Editas Medicine Stock (NASDAQ:EDIT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Editas Medicine alerts:Sign Up Key Stats Today's Range$2.48▼$2.7050-Day Range$2.10▼$3.4652-Week Range$0.91▼$4.12Volume1.15 million shsAverage Volume1.73 million shsMarket Capitalization$231.09 millionP/E RatioN/ADividend YieldN/APrice Target$5.10Consensus RatingHold Company Overview Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Read More Editas Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreEDIT MarketRank™: Editas Medicine scored higher than 84% of companies evaluated by MarketBeat, and ranked 166th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 7 hold ratings, and 2 sell ratings.Amount of Analyst CoverageEditas Medicine has only been the subject of 2 research reports in the past 90 days.Read more about Editas Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Editas Medicine are expected to grow in the coming year, from ($2.71) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 12.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Editas Medicine's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.58% of the float of Editas Medicine has been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Editas Medicine has recently decreased by 7.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.15 Percentage of Shares Shorted9.58% of the float of Editas Medicine has been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Editas Medicine has recently decreased by 7.86%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.47 News SentimentEditas Medicine has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Editas Medicine this week, compared to 4 articles on an average week.Search Interest25 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 79% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,649.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDIT Stock News HeadlinesEditas Medicine, Inc. (NASDAQ:EDIT) EVP Sells $12,751.29 in StockAugust 5, 2025 | insidertrades.comEditas Medicine to Host Webinar Announcing Lead In Vivo Development CandidateAugust 28 at 4:01 PM | globenewswire.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)Editas Medicine to Participate in Upcoming Investor ConferencesAugust 27 at 9:00 AM | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Editas Medicine (EDIT), Tilray (TLRY)August 27 at 7:38 AM | theglobeandmail.comWhy Editas Medicine Stock Was Skyrocketing This WeekAugust 16, 2025 | msn.comEditas Medicine price target raised to $6 from $4 at BairdAugust 13, 2025 | msn.comEditas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business UpdatesAugust 13, 2025 | finanznachrichten.deSee More Headlines EDIT Stock Analysis - Frequently Asked Questions How have EDIT shares performed this year? Editas Medicine's stock was trading at $1.27 at the start of the year. Since then, EDIT shares have increased by 102.4% and is now trading at $2.57. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.22. The company had revenue of $3.58 million for the quarter, compared to analyst estimates of $1.81 million. Editas Medicine had a negative net margin of 608.88% and a negative trailing twelve-month return on equity of 200.25%. When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Top institutional investors of Editas Medicine include Geode Capital Management LLC (2.35%), Bank of America Corp DE (1.20%), JPMorgan Chase & Co. (1.27%) and Kennedy Capital Management LLC (0.68%). Insiders that own company stock include Gilmore Neil O'neill, Baisong Mei, Michelle Robertson, Bruce Eaton, Jessica Hopfield, Mark S Shearman, Linda Burkly and Amy Parison. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Tesla (TSLA), Enovix (ENVX) and Luminar Technologies (LAZR). Company Calendar Last Earnings8/12/2025Today8/29/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EDIT CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees230Year Founded2013Price Target and Rating Average Price Target for Editas Medicine$5.10 High Price Target$12.00 Low Price Target$1.00 Potential Upside/Downside+98.4%Consensus RatingHold Rating Score (0-4)2.23 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$237.09 million Net Margins-608.88% Pretax Margin-608.88% Return on Equity-200.25% Return on Assets-68.57% Debt Debt-to-Equity RatioN/A Current Ratio2.77 Quick Ratio2.77 Sales & Book Value Annual Sales$32.31 million Price / Sales7.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book12.24Miscellaneous Outstanding Shares89,920,000Free Float88,032,000Market Cap$231.09 million OptionableOptionable Beta2.19 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:EDIT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.